The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK plc (LSE/NYSE:GSK) a annoncé lundi que l'Agence européenne des médicaments (EMA) a accepté d'examiner sa demande d'autorisation de mise sur le marché pour le linerixibat, un traitement expérimenta ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

– GSK a annoncé lundi que l’Agence européenne des médicaments a accepté d’examiner la demande d’autorisation de mise sur le ...

Le linerixibat agit en inhibant le transporteur iléal des acides biliaires (IBAT), réduisant les médiateurs du prurit en circulation. La FDA et l’EMA ont toutes deux accordé au médicament la ...

GSK annonce que l'Agence européenne des médicaments a accepté d'examiner la demande d'autorisation de mise sur le marché du ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

Linerixibat users recorded an average placebo-adjusted improvement of 0.72 points on a 10-point itch scale for the worst itch, measured using the WI-NRS scale, with reductions of that magnitude ...

THIS YEAR, the vibrant city of Amsterdam, the Netherlands played host to the European Association for the Study of ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Linerixibat improves pruritus and pruritus-associated sleep disturbances rapidly and significantly in patients with primary biliary cholangitis (PBC), according to a new study published in the Journal ...